TGF-β signaling and the role of inhibitory smads in non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 4, 2010, Pages 417-419

  Jeon, Hyo Sung ^a   Jen, Jin ^b  

^a Kyungpook National University School of Medicine   (South Korea)

^b MAYO CLINIC   (United States)

Author keywords

Non small cell lung cancer survival; Smads; Target based therapy; TGF signaling

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; AP 12009; INHIBITORY SMAD PROTEIN; LY 364947; PHOSPHOTRANSFERASE INHIBITOR; SB 505124; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 77950977675     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181ce3afd     Document Type: Short Survey

References (37)

1. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998;67: 753-791.
2. Kato Y, Habas R, Katsuyama Y, et al. A component of the ARC/ Mediator complex required for TGF beta/Nodal signalling. Nature 2002;418:641-646.
3. Roberts AB. TGF-beta signaling from receptors to the nucleus. Microbes Infect 1999;1:1265-1273.
4. Hayashi H, Abdollah S, Qiu Y, et al. The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell 1997;89:1165-1173. (Pubitemid 127678749)
5. Imamura T, Takase M, Nishihara A, et al. Smad6 inhibits signalling by the TGF-beta superfamily. Nature 1997;389:622-626. (Pubitemid 27446182)
6. Ebisawa T, Fukuchi M, Murakami G, et al. Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem 2001;20:12477-12480. (Pubitemid 37385151)
7. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signaling. Nature 2003;425:577-584. (Pubitemid 37280136)
8. Moustakas A, Heldin CH. Non-Smad TGF-beta signals. J Cell Sci 2005;118:3573-3584.
9. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000;342:1350-1358.
10. de Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 2000;92:1388-1402.
11. Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev 1996;7:93-102.
12. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 2003;100:8621-8623. (Pubitemid 36899145)
13. Dalal BI, Keown PA, Greenberg AH. Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 1993;143:381-389.
14. Hasegawa Y, Takanashi S, Kanehira Y, et al. Transforming growth factor-β1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 2001; 91:964-971.
15. Shim KS, Kim KH, Han WS, et al. Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. Cancer 1999;85:554-561.
16. Kim SJ, Im YH, Markowitz SD, et al. Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis. Cytokine Growth Factor Rev 2000;11:159-168. (Pubitemid 30169736)
17. Yanagisawa K, Osada H, Masuda A, et al. Induction of apoptosis by Smad3 and down-regulation of Smad3 expression in response to TGFbeta in human normal lung epithelial cells. Oncogene 1998;17:1743-1747. (Pubitemid 28482652)
18. Inoue T, Ishida T, Takenoyama M, et al. The relationship between the immunodetection of transforming growth factor-beta in lung adenocarcinoma and longer survival rates. Surg Oncol 1995;4:51-57.
19. Zhao L, Wang L, Ji W, et al. Elevation of plasma TGF-beta1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-cell lung cancer: a combined analysis from Beijing and Michigan. Int J Radiat Oncol Biol Phys 2009;74:1385-1390.
20. Yuan X, Liao Z, Liu Z, et al. Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol 2009;27:3370-3378.
21. Afrakhte M, Moren A, Jossan S, et al. Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members. Biochem Biophys Res Commun 1998;249:505-511. (Pubitemid 28431783)
22. Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 1999;397:710-713. (Pubitemid 29108392)
23. Bitzer M, von Gersdorff G, Liang D, et al. A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA. Genes Dev 2000; 14:187-197. (Pubitemid 30070984)
24. Nakao A, Afrakhte M, Moren A, et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 1997;389: 631-635. (Pubitemid 27446184)
25. Masui T, Wakefield LM, Lechner JF, et al. Type beta transforming growth factor is the primary differentiation-inducing serum factor for normal human bronchial epithelial cells. Proc Natl Acad Sci USA 1986;83:2438-2442. (Pubitemid 16026898)
26. Jeon HS, Dracheva T, Yang SH, et al. SMAD6 contributes to patient survival in non-small cell lung cancer and its knockdown reestablishes TGF-beta homeostasis in lung cancer cells. Cancer Res 2008;68:9686-9692.
27. Liu X, Lee J, Cooley M, et al. Smad7 but not Smad6 cooperates with oncogenic ras to cause malignant conversion in a mouse model for squamous cell carcinoma. Cancer Res 2003;63:7760-7768. (Pubitemid 37466707)
28. Kleeff J, Ishiwata T, Maruyama H, et al. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 1999;18: 5363-5372. (Pubitemid 29469224)
29. Javelaud D, Mohammad KS, McKenna CR, et al. Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res 2007;67:2317-2324. (Pubitemid 46424252)
30. Azuma H, Ehata S, Miyazaki H, et al. Effect of Smad7 expression on metastasis of mouse mammary carcinoma JygMC(A) cells. J Natl Cancer Inst 2005;97:1734-1746. (Pubitemid 41782283)
31. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-454.
32. DaCosta Byfield S, Major C, Laping NJ, et al. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2004;65:744-752. (Pubitemid 38264042)
33. Inman GJ, Nicolas FJ, Callahan JF, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002;62:65-74.
34. Ge R, Rajeev V, Subramanian G, et al. Selective inhibitors of type I receptor kinase block cellular transforming growth factor-beta signaling. Biochem Pharmacol 2004;68:41-50. (Pubitemid 38746540)
35. Bakin AV, Tomlinson AK, Bhowmick NA, et al. Phosphatidylinositol 3-kinase function is required for transforming growth factor betamediated epithelial to mesenchymal transition and cell migration. J Biol Chem 2000;275:36803-36810.
36. Ananth S, Knebelmann B, Gruning W, et al. Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 1999; 59:2210-2216. (Pubitemid 29217687)
37. Hau P, Jachimczak P, Schlingensiepen R, et al. Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 2007;17:201-212. (Pubitemid 47124417)